MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference

On September 10, 2020 MaxCyte, a global cell-based therapies and life sciences company, reported that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020 (Press release, MaxCyte, SEP 10, 2020, View Source;co-22nd-annual-global-investment-virtual-conference-301125117.html [SID1234564980]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT
Online access: View Source

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!